Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282183 | 0.88 | PDE4B (0.46) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL3277156 | 0.84 | KDM1A (0.49) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL3276980 | 0.82 | PRMT5 (0.47) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL3280041 | 0.82 | GPR119 (0.48) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL28983496 | 0.81 | PDE4D (0.44) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL4299761 | 0.80 | SCD (0.34) | — | |
| SCHEMBL1446426 | 0.80 | PDE4B (0.45) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL28983487 | 0.80 | PDE4D (0.45) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL28526179 | 0.79 | PDE4D (0.45) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL28983509 | 0.79 | PDE4D (0.43) | GPR119PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | HENNEQUIN LAURENT FRANCOIS ANDRE | 2010-11-04 | — | — | US | disclosed |
| US-7696214-B2 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2010-04-13 | — | — | US | disclosed |
| US-7160891-B2 | Quinazoline derivatives for the treatment of T cell mediated diseases | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB | 2006-11-16 | — | — | US | disclosed |
| US-7049438-B2 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2006-05-23 | — | — | US | disclosed |
| EP-1450808-B8 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| EP-1450808-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | disclosed |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
| EP-1450808-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| EP-1292594-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045395-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| WO-2001094341-A9 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | WO | disclosed |
| EP-1292594-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | AstraZeneca AB (SE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | TPD52L2, NQO2, H1-5 | GPR119 4039/4885PDE4D 1862/4885PDE4B 1641/4885 |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | NQO2, TOP1, TPD52L2 | GPR119 4072/4885PDE4D 2600/4885PDE4B 2453/4885 |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | CD4, HLA-DRB1, IFNG | GPR119 4488/4885PDE4D 3615/4885PDE4B 4132/4885 |
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | TPD52L2, NQO2, H1-5 | GPR119 4039/4885PDE4D 1862/4885PDE4B 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.